Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(75%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated375%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

NCT03220347
terminatedphase_1

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

NCT04324840
terminatedphase_1

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

NCT04047303
withdrawnphase_1

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

NCT05678283

Clinical Trials (4)

Showing 4 of 4 trials
NCT03220347Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Terminated
NCT04324840Phase 1

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Terminated
NCT04047303Phase 1

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Terminated
NCT05678283Phase 1

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4